Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study - Wikidata - awgldk - TriplyDB

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

http://www.wikidata.org/entity/Q35605535

about

The future of biologic agents in the treatment of Sjögren's syndrome Cellular targeting in autoimmunity Sjögren's syndrome: still not fully understood disease Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis.Multiple Roles for B-Lymphocytes in Sjogren's Syndrome Ocrelizumab: a step forward in the evolution of B-cell therapy The potential utility of B cell-directed biologic therapy in autoimmune diseases.Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling Targeting B cells with biologics in systemic lupus erythematosus.Treatment of systemic lupus erythematosus with epratuzumab.Novel aspects of Sjögren's syndrome in 2012.Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of Lupus.Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?Treating Sjögren's Syndrome: Insights for the Clinician Acupuncture for Primary Sjögren Syndrome (pSS) on symptomatic improvements: study protocol for a randomized controlled trial.Advances in human B cell phenotypic profiling.Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjögren syndrome.B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue.Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2 Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial Epratuzumab in the therapy of oncological and immunological diseases.Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies.B cell modulation in rheumatology B-cell targeting: a novel approach to immune intervention today and tomorrow.Translating co-stimulation blockade into clinical practice.Biologic treatments for systemic rheumatic diseases Oral manifestations of Sjögren's syndrome.Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.Novel targeted therapies for autoimmunity.Primary Sjogren's syndrome: too dry and too tired.Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept Emerging biotherapies for Sjögren's syndrome.Emerging small molecule and biological therapeutic approaches for the treatment of autoimmunity.What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis?Biological therapies in primary Sjögren's syndrome.Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.Biologics in oral medicine: Sjogren syndrome.CD22 and autoimmune disease.Sjögren's syndrome in older patients: aetiology, diagnosis and management.

P2860

Q24681044-83C0D578-881B-4B31-A1B5-C320C004D8EC Q26824580-BE124268-CF54-4A3C-9C05-F1FDC667313C Q26851943-9398CB98-2AA9-46F7-A50D-F07349D707D7 Q27686770-FC42D99B-9BD6-4212-AB61-E29FB289570C Q28068695-8BDAE2BE-DDA3-47D5-8DFE-36DBE8F26536 Q28245986-0CAE0866-6E40-49EB-865E-D81B357D60DF Q33377109-34C08AA1-A1C4-4FE1-9A14-3BD8609DA0D2 Q33691812-C93F14F7-86C5-4B61-ACD4-72E62268DA6D Q34232326-76BFA81E-2B21-469C-B3DB-0700C3B5493F Q34580559-686DC0EE-B4F3-47C1-B086-35475EBDAD1B Q34650103-FF395A3C-739E-4623-902E-EA7434C2910A Q35170984-9DCB9EA2-D313-46FA-9EA7-62887C6278EC Q35774612-9F3E3B7A-7862-4BC2-BEB2-DC5B59CACAB3 Q36056942-796912A2-3C6A-4DF7-9189-AE2A4EEB2E22 Q36254489-1B53F678-B2FB-47A7-8539-5F3303035719 Q36307080-617875B3-AD05-4023-AD3C-2BA76CFADFBD Q36318183-FC531A8C-E17A-49D7-B05C-7DEFCDEC5435 Q36392366-DF2C7D7F-0FE8-4650-8B7D-787D32EA7591 Q36430066-76F39A58-46D2-43AA-8D51-EDF3214BF984 Q36465459-41C7C48D-D373-4C33-A719-7805C5E119F4 Q36636619-B887E2FC-5B97-4C1E-BC73-F24A37D4D0EA Q36832137-4372F24E-6E41-4FEB-B924-E33F4A13A0E7 Q36878215-F9ACC1ED-5ABF-4E65-80D8-E4000C49CA55 Q36922233-BD7AA467-C982-42F4-8787-C77516EC0035 Q36972500-F9086AD5-81C9-4694-908A-C226EBB581BA Q37087438-A5602CD1-D82E-4C17-AC77-7FA6F1D43BB3 Q37117336-360A9BA4-91AA-4694-9620-424216751AE8 Q37126126-C37A4A16-9C37-4A28-98D5-C7932B97CD5A Q37614638-5BE4486B-6C4B-42CE-A3FA-F8A37AA59349 Q37690497-74109517-57F9-4930-9169-140BB0A431E4 Q37696041-F8426860-5D4F-4FFA-A65F-8FA47769B9ED Q37729176-9EDFD5FD-96B9-44B3-8E1B-0948A0A32833 Q37813704-1217A20D-969A-4E43-9CD7-E329C025A231 Q37849356-7ED12162-008C-4E71-A8E7-642BFD80AF5B Q37860347-C8F9ABD9-45AB-47D6-9F69-A29C1E40AD76 Q37884384-363A0745-39C8-41BA-BD8C-EB2B41DD508C Q37963474-98FB58F0-1BF9-4A87-A64C-C2A0B9678B85 Q38002156-0610149F-1C6B-4042-B67F-FCC21763568C Q38053491-801682D9-B177-4B3E-A199-6CE91F5DF487 Q38076070-B998D733-2EF2-4BB9-A24B-571CA889CB3B

P2860

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

http://www.wikidata.org/entity/Q35605535

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@ast

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@en

type

label

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@ast

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@en

prefLabel

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@ast

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@en

P1433

Q35605535-81E39882-24D3-4CD7-BA33-F537907206F2

P1476

Q35605535-348BC2C1-BFC4-41C9-9835-BDCCE0435A0A

P2093

Q35605535-2211AD0B-BEBB-4072-B195-93AB213CAB0F

Q35605535-3A430848-9A39-4E13-999C-EA7D58A1D503

Q35605535-5918E360-8696-43A8-896B-A76F541685C7

Q35605535-DC9678CB-B9CF-44B9-B049-A804EE42A816

Q35605535-F334599B-6E2C-4A14-ADAD-53A54F6F6484

Q35605535-FC19C8FA-05B6-453C-B639-93535EF8407E

P2860

Q35605535-18B58444-50AA-4E0F-AC8F-4A4587FAF98B

Q35605535-1C4C741C-3183-480F-9D62-F94D26AF4C53

Q35605535-22E87E48-09ED-484E-8DE0-9FDF70F00566

Q35605535-24659C92-9549-4E32-97DA-AF24FED4B149

Q35605535-37084408-C466-45E4-A97F-64CA87C8EA7C

Q35605535-431D0950-651E-4E88-8619-392F4E9FF880

Q35605535-44B8D790-C17F-41FE-B75B-C931A201432E

Q35605535-460693BA-87FD-4A52-8582-22E9E69A242B

Q35605535-4A8E6BE3-F359-4234-BC4F-CE299AFE89A8

Q35605535-4F616D66-2E1A-4BA4-8385-2D88B864B202

P2888

Q35605535-94CF4AEF-0296-42E4-8C94-7CE61DA959DF

P304

Q35605535-376663F6-B965-4B2B-9E0F-EEB98388D811

P31

Q35605535-04B523DB-D804-40F1-AD3A-6C9FBEBB268D

P356

Q35605535-2C482858-0752-4703-93E1-B8BCF98C4B26

P433

Q35605535-AD7D68C1-7CA3-42F7-AD0E-2CBCDAD353F2

P478

Q35605535-0806BAD2-6FCA-4E1F-894F-D7D3A02FDB23

P50

Q35605535-B69789DA-F384-4E34-9F1A-78E6169A5353

P577

Q35605535-1841F7FD-5DE2-44B2-987C-5FCCEAD18D22

P5875

Q35605535-639DC68A-FFF0-4B96-8C74-5E573C41BB33

P6179

Q35605535-E277F09F-119F-4B63-BF24-D3C35E31664A

P698

Q35605535-D53A7AE5-BF2C-468B-BEAE-7BFDF5D44AB0

P921

Q35605535-82635433-C06D-4408-9C42-B8D167367414

P932

Q35605535-80875022-B2FC-437E-BE6B-8DA742085730

P356

P1433

Arthritis Research and Therapy

P1476

Epratuzumab (humanised anti-CD ...... an open-label phase I/II study

@en

P2093

David M Goldenberg

http://www.w3.org/2001/XMLSchema#string

Laure Tant

http://www.w3.org/2001/XMLSchema#string

Nick K W Teoh

http://www.w3.org/2001/XMLSchema#string

Olivier Pradier

http://www.w3.org/2001/XMLSchema#string

Serge D Steinfeld

http://www.w3.org/2001/XMLSchema#string

William A Wegener

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

The role of CD22 and other inhibitory co-receptors in B-cell activation.

CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.

Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies.

Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome

Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK.

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab.

P2888

P304

R129

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/AR2018

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Gerd-Rüdiger Burmester

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6925623

http://www.w3.org/2001/XMLSchema#string

P6179

1018166128

http://www.w3.org/2001/XMLSchema#string

P698

16859536

http://www.w3.org/2001/XMLSchema#string

P921

P932

1779377

http://www.w3.org/2001/XMLSchema#string